

IN THE CLAIMS—CLEAN

Please amend the claims as follows:

D1 5. (Amended) The method of Claim 1, wherein the chemodenervating agent is selected from the group consisting of botulinum toxins type A, B, C, D, E, F, and G.

D2 6. (Amended) The method of Claim 1, wherein the chemodenervating agent is administered in conjunction with another anti-inflammatory agent.

D3 11. (Amended) A method for treating classic type 1 hypersensitivity, comprising the step of administering a chemodenervating agent to an affected area.

12. (Amended) The method of Claim 11, wherein the hypersensitivity is selected from the group consisting of hay fever and rhinitis.

IN THE CLAIMS—MARKED-UP

Please amend the claims as follows:

5. (Amended) The method of Claim 1, wherein the chemodenervating agent [includes] is selected from the group consisting of botulinum toxins type [A-G] A, B, C, D, E, F, and G.
6. (Amended) The method of Claim 1, wherein the chemodenervating agent is administered in conjunction with [an other] another anti-inflammatory agent(s).
11. (Amended) A method for treating classic type 1 hypersensitivity, comprising the step of administering a chemodenervating agent to [the] an affected area[s].
12. (Amended) The method of Claim 11, wherein the hypersensitivity [includes] is selected from the group consisting of hay fever and [rhinnitis]rhinitis.